The application for the 2024 NINDS Clinical Trials Methodology Course (CTMC) is currently open for the 2024 cohort.
The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective, interventional clinical trials. Applicants proposing large, multi-center trials will also be considered this year. The multi-center proposals should ideally be aligned with the focus areas of one of the established NINDS clinical research networks. Please see application instructions for more information.
There is a combination of distance learning activities and a REQUIRED residential course, along with small group mentorship from experienced clinical trialists and biostatisticians. The residential part of the course will be held June 3rd – 6th in Charlottesville, VA. Funding for travel (within the US) and accommodations will be provided for participants.
Who Should Apply?
Qualified applicants from clinical disciplines focused on neurological disease or injury (including, but not limited to pediatric and rare diseases), along with biostatisticians working on projects with clinical neuroscience researchers should apply. All preliminary trial ideas are encouraged, but it is REQUIRED that protocols be focused on the clinical neurosciences. Trainees should have content area mentors to assist them with the science and implementation of their project. A small number of projects may qualify for additional work using clinical trial simulation. Applicants proposing large, multi-center trials will also be considered this year. Please see the application instructions for more information.
The application submission deadline is March 4th, 2024 at 9am, Eastern Time. Application forms and additional details are available on the course website: https://siren.network/training/ctmc. Early applications may be considered for early acceptance.
The NINDS Clinical Trials Methodology Course is supported by the NeuroNEXT DCC Grant Number U01 NS077352 and is administered by the University of Michigan, the University of Iowa, Indiana University, and University of Viginia. Additional support is provided by the American Academy of Neurology.